Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy

J Antibiot (Tokyo). 2021 Oct;74(10):687-695. doi: 10.1038/s41429-021-00451-0. Epub 2021 Jul 30.

Abstract

Tumor cells are often exposed to hypoxia because of the lower oxygen supply deep inside the tumor tissues. However, tumor cells survive in these severe conditions by adapting to hypoxic stress through the induction of hypoxia-inducible factor 1 (HIF-1) signaling. HIF-1 activation is responsible for the expression of numerous HIF-1 target genes, which are related to cell survival, proliferation, angiogenesis, invasion, metastasis, cancer stemness, and metabolic reprogramming. Therefore, HIF-1 is expected to be a potential pharmacological target for cancer therapy. Small molecules derived from natural products (microbial origin, plant-derived, or marine organisms) have been shown to have unique chemical structures and biological activities, including HIF-1 inhibition. Several studies identified HIF-1 inhibitors from natural products. In this review, we summarize the current HIF-1 signaling inhibitors originating from natural products with a variety of modes of action, mainly focusing on microbial metabolites.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Biological Products / pharmacology*
  • Drug Delivery Systems
  • Humans
  • Hypoxia-Inducible Factor 1 / antagonists & inhibitors*
  • Neoplasms / drug therapy*
  • Signal Transduction / drug effects*

Substances

  • Antineoplastic Agents
  • Biological Products
  • Hypoxia-Inducible Factor 1